Loading
NeoGenomics' family of large gene tests for solid tumours, from a tissue sample or a blood draw.
PanTracer is NeoGenomics' portfolio of comprehensive genomic profiling tests for solid tumours. PanTracer Tissue sequences 517 genes in DNA and RNA for single-nucleotide variants, insertions and deletions, copy number changes, RNA fusions and splice variants, with microsatellite instability and tumour mutational burden, in 8 to 10 days; PanTracer Tissue + HRD adds a homologous recombination deficiency score (BRCA1/2 and a genomic instability score from loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions), validated for primary epithelial ovarian tumours; PanTracer Pro adds HRD and cancer-type-directed immunohistochemistry to the tissue test in one order. PanTracer LBx sequences 514 genes from circulating tumour DNA in 7 days, without RNA sequencing or HRD. NeoGenomics lists PanTracer Tissue and Pro as New York approved, and the HRD and LBx tests as not.
Tissue sequencing of 517 genes in DNA and RNA, or blood sequencing of 514 genes in circulating tumour DNA, for single-nucleotide variants, insertions and deletions, copy number changes and fusions.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"PanTracer" OR ABSTRACT:"PanTracer" OR TITLE:"NeoGenomics PanTracer" OR ABSTRACT:"NeoGenomics PanTracer" OR TITLE:"NEO PanTracer Tissue" OR ABSTRACT:"NEO PanTracer Tissue" OR TITLE:"NEO PanTracer Pro" OR ABSTRACT:"NEO PanTracer Pro" OR TITLE:"NEO PanTracer LBx" OR ABSTRACT:"NEO PanTracer LBx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PanTracer, not a curated reading list.
Shares Reference laboratories and companion-diagnostic testing, Homologous recombination deficiency (HRD), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares Homologous recombination deficiency (HRD), Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR) and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling and the tag test.
Shares NeoGenomics, Reference laboratories and companion-diagnostic testing, Next-generation sequencing (NGS), Comprehensive genomic profiling and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling and the tag test.
Shares NeoGenomics, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/